DLL3xB7H3 bsADC / Biocytogen - LARVOL DELTA

Bispecific antibody drug conjugates (bsADCs) targeting DLL3 and B7-H3 demonstrated potent anti-tumor activity in preclinical models of small cell lung cancer (SCLC) (AACR 2025) - "Tarlatamab, a T cell engager targeting DLL3, was recently approved for SCLC...In vitro, the bsAbs showed superior internalization in double positive cell lines than the parental monovalent arms and outperformed the naked antibodies of DS-7300 and rovalpituzumab (Rova)...The bsAbs for our lead bsADCs exhibited excellent stability under stress conditions, suggesting their suitability for CMC development. In summary, our DLL3xB7H3 bsADCs showed promising and superior in vitro and in vivo preclinical activities with first-in-class potential for SCLC treatment."

Preclinical • Brain Cancer • CNS Tumor • Endocrine Cancer • Glioblastoma • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • CD276 • DLL3